SVCM
ATXS

Saturn V Capital Management’s Astria Therapeutics ATXS Stock Holding History

Saturn V Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-990,663
Closed -$7.61M – 24
2023
Q4 		$7.61M Sell
990,663
-228,430
-19% -$1.26M 2.91% 15
2023
Q3 		$9.09M Buy
1,219,093
+581,236
+91% +$4.96M 3.81% 15
2023
Q2 		$5.31M Buy
637,857
+536,518
+529% +$6.19M 2.95% 16
2023
Q1 		$1.35M Sell
101,339
-68,154
-40% -$921K 1.01% 17
2022
Q4 		$1.56M Buy
+169,493
New +$1.75M 1.29% 18

Other funds holding ATXS

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Saturn V Capital Management's ATXS Position: Q1 2024 in Review

Saturn V Capital Management sold out of Astria Therapeutics (ATXS) in Q1 2024, closing a stake of 990,663 shares — an estimated $7.61M sold.

Saturn V Capital Management first reported a position in ATXS in Q4 2022 and held it in 5 quarters. The position peaked at $9.09M in Q3 2023. 102 funds tracked by Wall St. Rank hold ATXS as of Q1 2024.

  • Saturn V Capital Management reported no remaining Astria Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Saturn V Capital Management sold 990,663 Astria Therapeutics shares in Q1 2024, an estimated $7.61M.
  • Saturn V Capital Management first reported a position in Astria Therapeutics in Q4 2022 and held it in 5 quarters.
  • Saturn V Capital Management's Astria Therapeutics position peaked at $9.09M in Q3 2023.
  • 102 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2024.

Based on Saturn V Capital Management's 13F filing for Q1 2024, filed 15 May 2024.